Skip to main content

Table 4 Summary table of RFS rates observed in the prospective registry cohort and retrospective archival studies

From: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Study n Non-event follow-up time Event time Class 1 1.5-year RFS Class 2 1.5-year RFS
Median, years Median, years Percent (95% CI*) Percent (95% CI)
Initial validation (Gerami, 2015) 104 8.2 1.7 98% (95–100%) 70% (58–85%)
Independent validation 523 7.2 1.2 95% (92–97%) 67% (61–74%)
All retrospective studies to date 782 6.9 1.3 95% (93–97%) 67% (62–73%)
Current study 322 1.5 1.0 97% (95–100%) 77% (67–87%)
  1. *CI confidence interval